Short interest for Centessa Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Centessa Pharmaceuticals's stock. Short interest data is updated every two weeks.

Centessa Pharmaceuticals Stock (NASDAQ:CNTA), Short Interest Report

Centessa Pharmaceuticals

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFRM

AMCX

BILL

BTAI

BTTR

CENT

CLSK

CNTA

DOOR

EGAN

EMKR

EXPE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IBEX

IGMS

ILAG

ILMN

Intelligent Bio Solutions Inc. - Common Stock

INBS

IREN

LTRX

MLGO

MTRX

NGVC

NSTG

OCUL

PINS

PLCE

RNLX

SHCO

STRM

SUNW

SYBX

TCBP

TERN

TTWO

VIRC

ZJYL

Shares of  Take-Two Interactive Software, Inc.  (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.

Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ARVN

DOCN

LITE

PATH

POWI

SPSC

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday.

Shares of  SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results.

SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday

BELFB

BPMC

BPOP

CFFN

COLB

EGBN

FFWM

FIBK

FLEX

HCSG

HSII

IBRX

ITGR

MBLY

MORN

NOVA

NTGR

OPRA

PHAR

TROX

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.

IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals PLC

<p>Wells Fargo  analyst Steven Cahall   maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Underweight and lowers the price target from $3 to $2.5.</p>


Price Target

Analyst Ratings

SIRI

Wells Fargo Maintains Underweight on Sirius XM Holdings, Lowers Price Target to $2.5

<p>Alanna Zabel, a former yoga instructor for <a href="https://www.benzinga.com/real-estate/23/12/36158658/bezos-leaving-behind-a-massive-seattle-real-estate-portfolio-as-he-and-lauren-sanchez-plan-move-miam">Jeff Bezos's fiancee Lauren Sanchez</a>, has accused the ex-entertainment journalist of using her children's book idea without permission. </p>
<p>According to the Daily Mail, Zabel issued a cease-and-desist letter to Sanchez over the alleged intellectual property infringement.</p>
<p>&nbsp;"I'm deeply offended, and I am taking legal action with the book," Zabel said.</p>
<p>Their professional relationship, which began in 2007, ended shortly after Sanchez's 40th birthday in 2009 because of what Zabel described as Sanchez's penchant for gossip, which she found toxic, according to the Daily Mail report. They reconnected after Sanchez started dating Bezos, prompting Zabel to hope that Bezos might help promote her upcoming book about a space-traveling cat because it aligns with his interests in space travel and global conservation.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<p>Zabel said that in 2022, she shared the concept for her self-published children&#8217;s book &#8220;Dharma Kitty Goes to Mars&#8221; with Sanchez. She said she intended to donate the proceeds to the Bezos Earth Fund and Bezos Academy. Zabel also said that over the years, she gifted Sanchez copies of her other self-published children&#8217;s books and discussed them during their yoga sessions.</p>
<p>According to the Daily Mail, Zabel said she tried contacting Sanchez about her book proposal through emails and social media but received no response. While Bezos&#8217;s office offered her links to explore business development opportunities with Amazon.com Inc., her attempts to connect proved unsuccessful. Following this lack of communication and the March 5 announcement of Sanchez&#8217;s children&#8217;s book &#8220;The Fly Who Flew to Space,&#8221; Zabel decided to pursue legal action.</p>
<p>&nbsp;<strong>Trending:</strong></p>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<p>The initial cease and desist was reportedly sent to Sanchez and her publisher The Collective Book Studio on March 25, followed by a second notice on April 4.  Zabel is preparing to escalate the matter to a formal copyright infringement complaint by the end of the month if no response is received from Sanchez.</p>
<p>Allegations of intellectual property infringement often hinge on the ability to demonstrate that an idea was shared and copied without permission. In this instance, the yoga instructor says she shared her book concept with the entertainment journalist, providing details about the book and its intended charitable beneficiaries. The success of such claims can depend on the strength of the evidence presented, such as documented communication or witness testimony.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>


Real Estate

Jeff Bezos's Fiancee, Lauren Sanchez Is Accused Of Stealing Children's Book Idea From Ex-Yoga Teacher Who Quit Because She Was 'Toxic'

<p>Wells Fargo  analyst Joseph O'Dea   maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and lowers the price target from $255 to $244.</p>


Wells Fargo Maintains Underweight on Illinois Tool Works, Lowers Price Target to $244

<p>TD Cowen  analyst Marc Bianchi   maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and raises the price target from $305 to $320.</p>


TD Cowen Maintains Buy on Air Products & Chemicals, Raises Price Target to $320

<p>Wells Fargo  analyst Joseph O'Dea   maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and lowers the price target from $435 to $397.</p>


HUBB

Wells Fargo Maintains Equal-Weight on Hubbell, Lowers Price Target to $397

<p>TD Cowen  analyst Joshua Jennings   maintains TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Buy and raises the price target from $100 to $130.</p>


TMDX

TD Cowen Maintains Buy on TransMedics Gr, Raises Price Target to $130

<p>Wells Fargo  analyst Colin Langan   maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Equal-Weight and raises the price target from $134 to $139.</p>


Wells Fargo Maintains Equal-Weight on Lear, Raises Price Target to $139

<p><a href="https://www.federalreserve.gov/newsevents/pressreleases/monetary20240501a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/monetary20240501a.htm">https://www.federalreserve.gov/newsevents/pressreleases/monetary20240501a.htm</a></p>


Macro Economic Events

Economics

Federal Reserve

FOMC Is 'Strongly Committed' To Returning Inflation To 2% Target

<p>TD Cowen  analyst Gautam Khanna   maintains Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) with a Buy and raises the price target from $325 to $360.</p>


TD Cowen Maintains Buy on Trane Technologies, Raises Price Target to $360

Fed Will Maintain $35B Runoff Cap For Agency Debt, Mortgage-Backed Securities

<p>Wells Fargo  analyst Gabe Hajde   maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Equal-Weight and raises the price target from $76 to $84.</p>


Wells Fargo Maintains Equal-Weight on Crown Holdings, Raises Price Target to $84

Fed Says ' In recent months, there has been a lack of further progress toward the Committee's 2 percent inflation objective.'

<p>Wells Fargo  analyst Larry Biegelsen   maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Overweight and raises the price target from $364 to $381.</p>


Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $381

<p>TD Cowen  analyst Moshe Orenbuch   maintains OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) with a Buy and raises the price target from $58 to $60.</p>


TD Cowen Maintains Buy on OneMain Holdings, Raises Price Target to $60

<p>Wells Fargo  analyst Larry Biegelsen   maintains Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) with a Overweight and lowers the price target from $100 to $84.</p>


NARI

Wells Fargo Maintains Overweight on Inari Medical, Lowers Price Target to $84

<p>Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.45, along with a high estimate of $112.00 and a low estimate of $85.00. This upward trend is apparent, with the current average reflecting a 1.03% increase from the previous average price target of $92.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714586486_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Merit Medical Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Kristen Stewart</td>
<td>CL King</td>
<td>Announces</td>
<td>Buy</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$87.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merit Medical Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Merit Medical Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Merit Medical Systems's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Merit Medical Systems analyst ratings.</strong></a></p>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
<p>Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.</p>
<h3>Merit Medical Systems: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Merit Medical Systems displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>10.6%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Merit Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.51%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Merit Medical Systems's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.27%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Merit Medical Systems's ROA excels beyond industry benchmarks, reaching <strong>1.34%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Merit Medical Systems's debt-to-equity ratio is below the industry average at <strong>0.74</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MMSI

The Analyst Landscape: 11 Takes On Merit Medical Systems

<p>TD Cowen  analyst Bill Kirk   maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Hold and raises the price target from $269 to $271.</p>


LPLA

TD Cowen Maintains Hold on LPL Finl Hldgs, Raises Price Target to $271

FOMC Repeats No Rate Cuts Until Inflation Moves Sustainably Toward 2%

<p>PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $125.38, with a high estimate of $140.00 and a low estimate of $101.00. This upward trend is evident, with the current average reflecting a 8.24% increase from the previous average price target of $115.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714586476_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of PACCAR among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$121.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nick Housden</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$123.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$117.00</td>
<td>-</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$101.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PACCAR. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PACCAR compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of PACCAR's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of PACCAR's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PCAR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on PACCAR analyst ratings.</strong></a></p>
<h2>Discovering PACCAR: A Closer Look</h2>
<p>Paccar is a leading manufacturer of medium- and heavy-duty trucks under the premium brands Kenworth and Peterbilt, which are primarily sold in the NAFTA region and Australia, and DAF trucks, which are sold in Europe and South America. The company's trucks are sold through over 2,300 independent dealers globally. Paccar Financial Services provides retail and wholesale financing for customers and dealers, respectively. The company commands approximately 30% of the Class 8 market share in North America and 17% of the heavy-duty market share in Europe.</p>
<h3>PACCAR: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, PACCAR showcased positive performance, achieving a revenue growth rate of <strong>11.65%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> PACCAR's net margin excels beyond industry benchmarks, reaching <strong>15.61%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> PACCAR's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>8.89%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> PACCAR's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.59%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> PACCAR's debt-to-equity ratio is below the industry average at <strong>0.91</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PCAR

The Latest Analyst Ratings For PACCAR

<p>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Exelixis, revealing an average target of $26.4, a high estimate of $28.00, and a low estimate of $25.00. This upward trend is evident, with the current average reflecting a 6.67% increase from the previous average price target of $24.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714586466_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Exelixis analyst ratings.</strong></a></p>
<h2>About Exelixis</h2>
<p>Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<h3>Exelixis's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Exelixis showcased positive performance, achieving a revenue growth rate of <strong>13.15%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>17.83%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.71%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Exelixis's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>2.89%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.08</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EXEL

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Centessa Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cnta-stock-quote/"><strong>CNTA</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Centessa Pharmaceuticals reported earnings per share of -38 cents. This was above the analyst estimate for EPS of -48 cents.</li><li>The company reported revenue of $6.85 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/cnta-stock-earnings-centessa-pharmaceuticals-for-q4-of-2023/">CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and Centessa Pha...

Analysts' Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)

Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on April 9. David Risinger has given...

Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results

The latest update is out from Centessa Pharmaceuticals (CNTA). Centessa Pharmaceuticals has announced FDA clearance for the Phase 1 trial of their ...

Centessa Pharmaceuticals Advances Narcolepsy Drug Trials

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT – Research Report), Struc...

Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Centessa Pharmaceuticals announces $100M proposed public offering of American Depositary Shares

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), Centess...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Centessa Pharmaceuticals prices $100M ADS offering

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

ATNM

CORT

GPCR

ISRG

Press Releases

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Health Care

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference

Earnings

General

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Financing

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Centessa Pharmaceuticals Stock (NASDAQ:CNTA), Short Interest Report

People Also Watch